HK1117427A1 - Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer - Google Patents

Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Info

Publication number
HK1117427A1
HK1117427A1 HK08112329.9A HK08112329A HK1117427A1 HK 1117427 A1 HK1117427 A1 HK 1117427A1 HK 08112329 A HK08112329 A HK 08112329A HK 1117427 A1 HK1117427 A1 HK 1117427A1
Authority
HK
Hong Kong
Prior art keywords
parapoxviruses
biochemotherapy
cancer
treatment
combination
Prior art date
Application number
HK08112329.9A
Other languages
English (en)
Inventor
Olaf Weber
Original Assignee
Aicuris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1117427(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh filed Critical Aicuris Gmbh
Publication of HK1117427A1 publication Critical patent/HK1117427A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK08112329.9A 2005-11-24 2008-11-10 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer HK1117427A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025600 2005-11-24
PCT/EP2006/009855 WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1117427A1 true HK1117427A1 (en) 2009-01-16

Family

ID=37654955

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08112329.9A HK1117427A1 (en) 2005-11-24 2008-11-10 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Country Status (15)

Country Link
US (1) US7897159B2 (de)
EP (1) EP1951274B1 (de)
JP (1) JP5164849B2 (de)
CN (1) CN101312737B (de)
AR (1) AR057922A1 (de)
AT (1) ATE450266T1 (de)
CA (1) CA2630833C (de)
DE (1) DE602006010902D1 (de)
DK (1) DK1951274T3 (de)
ES (1) ES2335308T3 (de)
HK (1) HK1117427A1 (de)
PL (1) PL1951274T3 (de)
PT (1) PT1951274E (de)
TW (1) TWI415617B (de)
WO (1) WO2007059821A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3730139B1 (de) 2008-06-17 2023-08-16 Wyeth LLC Antineoplastische kombinationen mit hki-272 und vinorelbin
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816139A1 (de) 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
WO2002004002A2 (de) * 2000-07-11 2002-01-17 Bayer Aktiengesellschaft Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
US20060099224A1 (en) * 2002-08-12 2006-05-11 David Kirn Methods and compositions concerning poxviruses and cancer

Also Published As

Publication number Publication date
ATE450266T1 (de) 2009-12-15
CA2630833A1 (en) 2007-05-31
PL1951274T3 (pl) 2010-05-31
CA2630833C (en) 2015-01-06
US7897159B2 (en) 2011-03-01
CN101312737A (zh) 2008-11-26
JP5164849B2 (ja) 2013-03-21
PT1951274E (pt) 2009-12-14
WO2007059821A1 (en) 2007-05-31
AR057922A1 (es) 2007-12-26
DE602006010902D1 (de) 2010-01-14
TW200738250A (en) 2007-10-16
JP2009517347A (ja) 2009-04-30
US20090035269A1 (en) 2009-02-05
TWI415617B (zh) 2013-11-21
DK1951274T3 (da) 2010-02-01
CN101312737B (zh) 2012-11-14
EP1951274A1 (de) 2008-08-06
ES2335308T3 (es) 2010-03-24
EP1951274B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
IL186662A0 (en) Combination cancer therapy with
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
HK1201182A1 (en) Pegylated il-10 for use in treating cancer or tumor il-10
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
EP1940456A4 (de) Wwox-gen, vektoren damit und seine verwendung bei der krebsbehandlung
SI2358697T1 (sl) Spojine izoindolina za uporabo pri zdravljenju raka
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
EP1868435A4 (de) Kombinationen, verfahren und zusammensetzungen zur behandlung von krebs
PL2564872T3 (pl) Mazindol sam lub w kombinacji z żelazem do leczenia deficytu uwagi/nadpobudliwości
AU2006251167A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
AU2006251169A8 (en) Tetrahydropyridothiophenes for use in the treatment of cancer
HK1117427A1 (en) Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
GB0517387D0 (en) Combinations for the treatment of cancer
HK1151971A1 (en) Compounds for use in the treatment of cancer
ZA200709542B (en) Combination therapy in the treatment of cancer
AU307436S (en) Angle grinder
AU303295S (en) Belt
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
IL190334A0 (en) Pyridylsulfonamide derivatives, their manufacture and use as antineoplastic agents
EP1917041A4 (de) Verwendung von fruktosebasierten therapien zur krebsbehandlung
IL185518A0 (en) 1,3-thiazole-5-carboxamides useful as cancer chemotherapeutic agents
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
WO2007035961A3 (en) Anti-cancer therapies
GB0507685D0 (en) Cancer treatment

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141012